ThirtyFiveBio
Lisa Shoesmith has extensive experience in finance and management roles, having worked in various companies such as M:M Bio, Grey Wolf Therapeutics, Pathios Therapeutics, and ThirtyFiveBio. Prior to these roles, Lisa served as a General Manager at Really Good Limited and University of Warwick and as a Financial Controller at mondus.com. Lisa graduated from Sheffield Hallam University with a Bachelor's Degree in Accountancy & Management Control.
ThirtyFiveBio
ThirtyFiveBio is an early-stage drug discovery company that was established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of GPR35. We are currently engaged in a fully enabled drug discovery program to identify novel small-molecule modulators of GPR35